Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

753 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ravulizumab and Efgartigimod in Myasthenia Gravis: A Real-World Study.
Stascheit F, Sousa CDF, Aigner A, Behrens M, Keller CW, Klotz L, Lehnerer S, Stein M, Herdick M, Doksani P, Gerischer LM, Hoffmann S, Lazaridis K, Tzartos J, Wiendl H, Meisel A, Lünemann JD. Stascheit F, et al. Among authors: wiendl h. Neurol Neuroimmunol Neuroinflamm. 2025 Jan;12(1):e200331. doi: 10.1212/NXI.0000000000200331. Epub 2024 Nov 27. Neurol Neuroimmunol Neuroinflamm. 2025. PMID: 39602677 Free PMC article.
Monoclonal antibodies in neuroinflammatory diseases.
Klotz L, Wiendl H. Klotz L, et al. Among authors: wiendl h. Expert Opin Biol Ther. 2013 Jun;13(6):831-46. doi: 10.1517/14712598.2013.767329. Epub 2013 Mar 22. Expert Opin Biol Ther. 2013. PMID: 23521026 Review.
L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients.
Schwab N, Schneider-Hohendorf T, Posevitz V, Breuer J, Göbel K, Windhagen S, Brochet B, Vermersch P, Lebrun-Frenay C, Posevitz-Fejfár A, Capra R, Imberti L, Straeten V, Haas J, Wildemann B, Havla J, Kümpfel T, Meinl I, Niessen K, Goelz S, Kleinschnitz C, Warnke C, Buck D, Gold R, Kieseier BC, Meuth SG, Foley J, Chan A, Brassat D, Wiendl H. Schwab N, et al. Among authors: wiendl h. Neurology. 2013 Sep 3;81(10):865-71. doi: 10.1212/WNL.0b013e3182a351fb. Epub 2013 Aug 7. Neurology. 2013. PMID: 23925765
Fingolimod treatment promotes regulatory phenotype and function of B cells.
Grützke B, Hucke S, Gross CC, Herold MV, Posevitz-Fejfar A, Wildemann BT, Kieseier BC, Dehmel T, Wiendl H, Klotz L. Grützke B, et al. Among authors: wiendl h. Ann Clin Transl Neurol. 2015 Feb;2(2):119-30. doi: 10.1002/acn3.155. Epub 2015 Jan 16. Ann Clin Transl Neurol. 2015. PMID: 25750917 Free PMC article.
Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor).
Klotz L, Grützke B, Eveslage M, Deppe M, Gross CC, Kirstein L, Posevitz-Fejfar A, Schneider-Hohendorf T, Schwab N, Meuth SG, Wiendl H. Klotz L, et al. Among authors: wiendl h. BMC Neurol. 2015 Jun 23;15:96. doi: 10.1186/s12883-015-0354-9. BMC Neurol. 2015. PMID: 26099927 Free PMC article.
Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society.
Melzer N, Ruck T, Fuhr P, Gold R, Hohlfeld R, Marx A, Melms A, Tackenberg B, Schalke B, Schneider-Gold C, Zimprich F, Meuth SG, Wiendl H. Melzer N, et al. Among authors: wiendl h. J Neurol. 2016 Aug;263(8):1473-94. doi: 10.1007/s00415-016-8045-z. Epub 2016 Feb 17. J Neurol. 2016. PMID: 26886206 Free PMC article. Review.
753 results